ENSC — Ensysce Biosciences Share Price
0.000.00%
Last trade - 00:00- $3.84m
- $0.36m
- $2.23m
- 31
- 38
- 24
- 21
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.01 | ||
| Price to Tang. Book | 1.01 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.17 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -290.86% | ||
| Return on Equity | -589.74% | ||
| Operating Margin | -572.54% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 3.53 | 2.52 | 2.23 | 1.2 | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -82.98 | +978.51 | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. The TAAP platform is designed to improve the care of patients with chronic pain while reducing the human and economic costs associated with prescription opioid drug abuse. The MPAR platform, when combined with its TAAP prodrugs, is designed to seek to prevent abuse of prescription drugs but also to reduce overdose occurrences. Additionally, nafamostat di-mesylate (nafamostat), which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- September 11th, 2017
- Public Since
- December 1st, 2017
- No. of Shareholders
- 71
- No. of Employees
- 7
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 7,585,172
- Address
- 7946 Ivanhoe Avenue, Suite 201, LA JOLLA, 92037
- Web
- https://ensysce.com/
- Phone
- +1 8582634196
- Contact
- Shannon Devine
- Auditors
- Moss Adams LLC
Upcoming Events for ENSC
Ensysce Biosciences Inc Annual Shareholders Meeting
Q3 2024 Ensysce Biosciences Inc Earnings Release
Similar to ENSC
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Ensysce Biosciences share price?
As of Today at 20:31 UTC, shares in Ensysce Biosciences are trading at $0.50. This share price information is delayed by 15 minutes.
How has the Ensysce Biosciences share price performed this year?
Shares in Ensysce Biosciences last closed at $0.50 and the price had moved by -76.3% over the past 365 days. In terms of relative price strength the Ensysce Biosciences share price has underperformed the S&P500 Index by -81.14% over the past year.
What are the analyst and broker recommendations for Ensysce Biosciences?
The overall consensus recommendation for Ensysce Biosciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Ensysce Biosciences dividend yield?
Ensysce Biosciences does not currently pay a dividend.
Does Ensysce Biosciences pay a dividend?
Ensysce Biosciences does not currently pay a dividend.
When does Ensysce Biosciences next pay dividends?
Ensysce Biosciences does not currently pay a dividend.
How do I buy Ensysce Biosciences shares?
To buy shares in Ensysce Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Ensysce Biosciences?
As of the previous close price of $0.50, shares in Ensysce Biosciences had a market capitalisation of $3.79m.
Where are Ensysce Biosciences shares listed?
Here are the trading details for Ensysce Biosciences:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ENSC
What kind of share is Ensysce Biosciences?
Based on an overall assessment of its quality, value and momentum Ensysce Biosciences is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Ensysce Biosciences share price forecast for 2024?
The analyst consensus target price for shares in Ensysce Biosciences is $10.75. That is 2049.57% above the last closing price of $0.50.
Analysts covering Ensysce Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$1.64 for the next financial year.
What is the trend in the Ensysce Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ensysce Biosciences. Over the past six months, its share price has underperformed the S&P500 Index by -57.98%.
As of the last closing price of $0.50, shares in Ensysce Biosciences were trading -49.39% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Ensysce Biosciences PE Ratio?
The Ensysce Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Ensysce Biosciences?
We do not have data on Ensysce Biosciences' directors